In BioPharma Review, the NYU Biotech Club will deconstruct the underlying science and business behind individual Biotech/Pharmaceutical Companies in order to gain an in-depth understanding of their business ventures and their prospects for the future in this industry.
Please check out these companies if you are interested in puttting together an analysis.
The following are links to analyses written by Biotech Club members:
Cougar Biotechnology powerpoint
Cougar Biotechnology (COUG) is a publicly traded company focused on developing novel treatments for cancer. The company is developing CB7630 (Abiraterone Acetate), a small molecule for the treatment of hormone refractory prostate cancer (HRPC), and has completed several clinical trials demonstrating its efficacy. The National Cancer Center reports that there are over 186,000 [...]
Zogenix Corporate Analysis powerpoint
Eurand Pharmaceutical Corporate Analysispowerpoint
Aegerion: Capitalize on Cholesterolpowerpoint
Cholesterol lowering drugs make up over 35 billion dollars in sales in 2006, more than ten percent of worldwide pharmaceutical company revenue. Healthcare companies on average spend over 80 dollars per member annually to fill cholesterol prescriptions; a whopping 11 percent of all prescription filled. The American Heart Association estimates that 34.5 million people in the US have high cholesterol and over 100 million are borderline high. Furthermore about 15 percent of people 20 and older and one in four people 65 and older are prescribed statins, one of the most common cholesterol medications. In short, cholesterol is big money and is the biggest chunk of money for the pharmaceutical industry. Aegerion is looking for a piece of that money.
Targanta Therapeutics: Antimicrobial Resistance
Targanta Therapeutics (TARG) filed for an IPO in early October 2007. They are a biopharmaceutical company focused on the development and commercialization of innovative antibiotics for serious infections. Their important therapeutic in development is oritavancin, a novel semi-synthetic glycopeptide antibiotic, for the treatment of serious gram-positive bacterial infections. In order to properly evaluate the current market for serious bacterial infections we first need to brush up on antibiotic resistant microbial pathogens. Let’s get started.
Cancer Vaccines - Dendritic Cells
Overview of the current status of cancer vaccines
Cancer has been on the rise since the average human lifespan has increased so dramatically over the last century. And the numbers are going up since USA, Europe and China are growing older at a fast pace. Roughly there are 10 million new cases of cancer worldwide. Cancer vaccines are projected to cost about $15,000-20,000 per patient per year. The human benefits of developing cancer vaccine would be vast, from millions of patients cured to billions of dollars pocketed. The race has started fairly recently and so far we have only two US FDA approved vaccines that are prophylaxis for the development of cervical cancer - Gardasil, which prevents infection with certain subtypes of human papilloma virus that together cause 70 percent of cervical cancer cases worldwide and a vaccine targeted for prevention of Hepatitis B, a virus associated with the development of liver cancer. As many as 13 more approvals are expected to come by 2012 as reported by Kalorama Information. Please note that none of the approved vaccines to date actually treat patients who have developed cancer, rather they are preventative vaccines fighting viral agents that are capable of causing cancer.
|
